Navigation Links
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, demonstrating that the addition of vandetanib to docetaxel resulted in a statistically significant improvement in progression-free survival (PFS), the length of time a patient lives without their cancer growing (hazard ratio [HR] 0.79, 97.58% CI 0.70-0.90; P<0.001. Median PFS: 14.0 weeks vs. 17.3 weeks, favoring vandetanib). Vandetanib is the first oral targeted therapy to show evidence of clinical benefits when added to chemotherapy in a Phase III study in second line advanced NSCLC(1).

To view the Multimedia News Release, go to:

ZODIAC is a randomized, double-blind, placebo-controlled Phase III study evaluating the combination of vandetanib 100mg with docetaxel versus docetaxel alone. The study enrolled 1391 patients previously treated with one prior anti-cancer therapy for advanced NSCLC.

Data from ZEAL(2), a smaller Phase III study also featured on this year's ASCO program, are supportive of ZODIAC although the primary endpoint did not reach statistical significance in the ZEAL study (hazard ratio [HR] 0.86, 97.58% CI 0.69-1.06; P=0.108. Median PFS: 11.9 weeks vs. 17.6 weeks, favouring vandetanib). The combination of vandetanib plus pemetrexed did show a positive trend in prolongation of PFS compared with pemetrexed alone.

ZEAL is a randomized, double-blind, placebo-controlled Phase III study evaluating vandetanib 100mg plus pemetrexed versus pemetrexed alone. The study enrolled 534 patients previously treated with one prior anti-cancer therapy for advanced NSCLC.

Evaluation of secondary endpoints in the ZODIAC and ZEAL studies showed that the addition of vandetanib to chemotherapy significantly improved objective response rate, which is a measurement of tumor shrinkage (ZODIAC: 17% vs. 10%, P<0.001; ZEAL: 19.1% vs. 7.9%, P<0.001), the studies also showed that adding vandetanib to chemotherapy resulted in a significantly longer time to deterioration of disease related symptoms (ZODIAC: HR 0.78, P=0.002, FACT-L Lung Cancer Subscale; ZEAL: HR 0.61, P=0.004, Lung Cancer Symptom Scale). Overall survival in both studies showed a positive trend, although they did not reach statistical significance (ZODIAC Study: HR 0.91, 97.52% CI 0.78-1.07: P=0.196; ZEAL Study: HR 0.86, 97.54% CI 0.65-1.13; p=0.219).

The observed safety profile in both studies was consistent with previous studies with vandetanib in NSCLC. The most common adverse events associated with vandetanib included rash, diarrhea and hypertension (ZEAL); rash, diarrhea and neutropenia (low white blood cell count) (ZODIAC). Incidence of protocol-defined QTc prolongation was <2.0 percent in both studies and was not associated with symptoms.

"There are more deaths from lung cancer alone than from breast, colon, and prostate cancers combined - and it's extremely difficult to treat," said Professor Roy Herbst, M.D., Ph.D., The University of Texas M. D. Anderson Cancer Center, Texas, Principal Investigator on the ZODIAC study. "The ZODIAC study showed adding vandetanib to chemotherapy improved progression-free survival, in patients who have few, if any options for treatment."

Results from a third Phase III study, ZEST(3), were also presented at this year's ASCO. While the primary objective of demonstrating a statistically significant prolongation of PFS for vandetanib was not met in this study, in a pre-planned non-inferiority analysis, vandetanib was shown to have similar efficacy to erlotinib for PFS and OS (PFS: hazard ratio [HR] 0.98, 95.22% CI 0.87-1.10; P=0.721; OS: HR 1.01, 95.08% CI 0.89-1.16; P=0.830). Objective response rate and symptom control were also similar for both treatments (ORR: both 12%; symptoms: pain, HR 0.96, P=0.583; dyspnea, HR 1.08, P=0.333; cough, HR 0.94, P=0.403).

The ZEST study was a randomized, double-blind, Phase III study evaluating the efficacy of vandetanib 300mg versus erlotinib 150mg. The study enrolled 1240 patients with locally advanced or metastatic NSCLC after failure of at least one prior anti-cancer therapy.

The most common adverse events observed in the ZEST study were rash, diarrhea and hypertension. Incidence of protocol-defined QTc prolongation was 5.1 percent in the vandetanib arm.

AstraZeneca plans to submit a regulatory submission for the use of vandetanib 100mg in combination with chemotherapy for patients with advanced NSCLC in the first half of 2009.

Evaluation of vandetanib is ongoing, as monotherapy or in combination with other anti-cancer therapies in a range of tumor types, including thyroid cancer.

Results from the ZEPHYR (300mg monotherapy study in EGFR failures in advanced NSCLC, Phase III) and ZETA (300 mg monotherapy in advanced medullary thyroid cancer, Phase III) studies will be available during the second half of 2009.

ZACTIMA(TM) is a trademark of the AstraZeneca group of companies.

About lung cancer

  • Over 1.35 million new cases of lung cancer are diagnosed every year and nearly 1.2 million people die as a result of this devastating disease - more than breast, colon and prostate cancer combined(4).
  • Non-small cell lung cancer accounts for around 85% of all lung cancers(5).
  • If lung cancer is detected at early stages, before it has spread to other organs or lymph nodes, around half of patients can survive for five years or more. However, few lung cancers are found at this early stage and it is normally diagnosed at the advanced stage, when five year survival falls to approximately 15%(6).

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit:

The statements contained herein include forward-looking statements. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of the preparation of this press release and the Company undertakes no obligation to update these forward-looking statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those risk factors identified in the Company's Annual Report/Form 20-F for 2008. Nothing contained herein should be construed as a profit forecast.

Reference List

(1) Herbst, R. et al. Vandetanib plus docetaxel vs docetaxel as 2nd-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). ABS 31495. ASCO. 2009.

(2) De Boer, R. et al. Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). ABS 31867, ASCO. 2009.

(3) Natale, R. et al. Vandetanib versus erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) after failure of at least 1 prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). ABS 31610. ASCO. 2009.

(4) Ferlay, J. et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARC Press, 2004.

(5) Ginsberg RJ. et al. Cancer: Principles and Practices of Oncology. 5th ed; 858-911. 1997. 6th ed. 925-983. 2001.

(6) Bepler G. Lung cancer epidemiology and genetics. J Thorac Imaging 1999; 14(4):228-234.

SOURCE AstraZeneca Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
2. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
3. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
4. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
5. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
6. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
7. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
8. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
11. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
Post Your Comments:
(Date:10/9/2015)... SAN DIEGO , Oct. 9, 2015 ... meeting (Infectious Disease Society of America ) regarding the ... a transplant patient on a respirator who was co-infected ... 130). Over a five-day course of therapy, O 2 ... and the patient was able to go off the ...
(Date:10/9/2015)... 2015 Der " JCA-Mauvernay Award ... Kondo und Dr.   Junko Takita    --> ... geht an Dr.   Yutaka Kondo und Dr. ... " JCA-Mauvernay Award   2015 " geht ... Takita    ™ , das weltweit tätige Schweizer Biopharmazieunternehmen, ...
(Date:10/8/2015)...  "They really did surround me with care," said ... team, after a routine appointment for a sore wrist ... 79-year-old Kaiser Permanente Senior Advantage member from ... she thought was tendinitis from quilting. Thanks to the ... she was diagnosed with and successfully treated for early-stage ...
Breaking Medicine Technology:
... 11, 2011 ViroPharma Incorporated (Nasdaq: ... that Halozyme has granted ViroPharma an exclusive worldwide ... proprietary drug delivery platform using Halozyme,s recombinant human ... C1 esterase inhibitor. Additionally, Halozyme has agreed not to ...
... 11, 2011 The national Tourette Syndrome Association (TSA) ... collaboration on a clinical trial to determine the potential ... symptoms of the neurological disorder Tourette Syndrome (TS). ... history that TSA has collaborated with the pharmaceutical industry ...
Cached Medicine Technology:
(Date:10/10/2015)... , ... October 10, 2015 , ... The sixth annual ... on the growth of cybercrime costs for US companies. The New York Times broke ... 6th. With averages showing increases hovering around 20% among the companies surveyed, it only ...
(Date:10/10/2015)... Arbor, MI (PRWEB) , ... October 10, 2015 , ... ... City, MO. , On the heels of the release of the Institute of ... of tools, and their integration with Cerner solutions that assist healthcare providers and consumers ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
(Date:10/9/2015)... ... October 09, 2015 , ... A new health tool ... Aid, is now available online ( ) – just in time for the ... officially begins in October. However, for many in the U.S., the real start of ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... a special promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. ... are almost invisible against the teeth, which allow patients to complete treatment in ...
Breaking Medicine News(10 mins):
... (HealthDay News) -- Drinking too much alcohol can lead to ... the most common cause of HIV infection and finding ways ... health efforts to prevent HIV/AIDS. Alcohol use has long ... whether unsafe sex associated with alcohol use actually led to ...
... MONDAY, Dec. 12 (HealthDay News) -- Breast cancer survivors ... treatment with radiation and/or chemotherapy, a new study says. ... and treatment-specific ways that these cancer therapies impair cancer ... Moffitt Cancer Center and Research Institute in Tampa, Fla., ...
... , Researchers at the Norwegian University of Life Sciences ... new method for detailed analyses of electrical activity in ... can help doctors and researchers to better interpret ... considerable steps forward in terms of interpreting for example ...
... has found that alcohol consumption directly impacts a person,s intention to ... the stronger becomes your intention to engage in unsafe sex. ... infection, and it is a main risk factor for the global ... prevent unsafe sex, HIV incidence in most high income countries (such ...
... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
... Researchers at the Stanford University School of Medicine report ... physical force contributes to scarring in mice. "Our ... the mechanical environment can directly increase inflammation, which is ... and associate chair of surgery. Mice genetically engineered ...
Cached Medicine News:
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... Distriman is a ... that is designed to ... used with Gilson DistriTip ... polypropylene syringes with level ...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... Plus, a handheld manual dispenser, is ideal ... long series pipetting. Its increased volume selection ... research tasks, and its smooth handling reduces ... The nine Combitips allow a wider range ...
Medicine Products: